Monash study finds increased risk of autoimmune disease in stone bench-top industry, raising concerns for screening

In what could be a preview of an even greater disease burden for those workers in the artificial stone benchtop industry, Monash researchers have conducted a large study finding that those workers exposed to silica dust show a higher incidence of blood markers that are the hallmark of autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

In June this year the manufacture, supply and installation of engineered stone benchtops was banned because of the high incidence of the deadly lung disease, silicosis, in this sector.

The study, published in the journal, Occupational and Environmental Medicine and led by Professor Karen Walker-Bone, studied a cohort of over 1200 current and former stone benchtop industry workers in Victoria who were offered free screening for silicosis and related disorders between 2019 and 2021. The researchers looked for symptoms or diagnoses of autoimmune disease as well as markers in the blood that could indicate early stages of autoimmune disease.

Amongst the 1238 workers 0.9% were confirmed with autoimmune disease, however almost one quarter (24.6%) had detectable anti-nuclear antibodies – 24.6% compared to less than 6% in similarly aged male controls.

Of the 24.3% of the cohort diagnosed with silicosis, 6.6% had very high levels of anti-nuclear antibodies. Importantly the researchers also found associations between autoantibodies and age, smoking, silicosis, and intensity of silica dust exposure.

According to Professor Walker-Bone, the proportion of workers with detectable markers for autoimmune disease was considerably higher than the 5-9% expected in the general population.

“This data suggests that – as well as screening for silicosis in these workers, they should also be screened for autoimmune disease, as these individuals need specialised management and may be entitled to compensation,” Professor Walker-Bone said.

While cases of autoimmune disease have also been reported in engineered stone benchtop industry workers, this is the first study to look at workers before they develop silicosis.

The finding of detectable markers in the blood of autoimmune disease may be an indicator of the worker developing the disease in decades to come, according to Professor Walker-Bone. “Although having detectable autoantibodies in isolation is not diagnostic of an autoimmune disease, their presence in certain rheumatic diseases, such as SLE and RA, has been shown to predate clinical features often by many years,” she said, prompting calls for the monitoring of autoimmune diseases in this group of workers, in addition to screening for silicosis, the study authors said.

“One concern is that a number of those with detectable autoantibodies will go on to manifest clinical disease with prolonged follow-up. However, the government screening clinics for the diagnosis of silicosis are not set up to bear the costs of longer-term follow-up of workers with high exposure who do not yet have detectable silicosis, let alone those who may /may not develop autoimmune disease,” Professor Walker-Bone said.

Read the full paper in Occupational and Environmental Medicine. Autoimmune diseases, autoantibody status and silicosis in a cohort of 1238 workers from the artificial stone benchtop industry. 10.1136/oemed-2024-109526